This Article Full Text Full Text (PDF) CME: Take the course for this article: Three Emerging New Drugs for NSCLC-Pemetrexed, Bortezomib, and Cetuximab eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dubey, S. Articles by Schiller, J. H. Search for Related Content PubMed PubMed Citation Articles by Dubey, S. Articles by Schiller, J. H.

Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and Cetuximab

University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA

Correspondence: Joan H. Schiller, M.D., K4/548, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA. Telephone: 608-263-5389; Fax: 608-265-8131; e-mail: jhschill{at}facstaff.wisc.edu

Despite advances made in cytotoxic chemotherapy, the prognosis for patients with non-small cell lung cancer (NSCLC) continues to be poor. New, more effective drugs must be identified and developed to improve the outcome of these patients. Three drugs with promising activity in NSCLC are pemetrexed (Alimta^®; Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com), bortezomib (Velcade^®; Millennium Pharmaceuticals, Inc., Cambridge, MA, http://www.mlnm.com), and cetuximab (Erbitux^®; ImClone Systems, Inc., New York, NY, http://www.imclone.com). Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, enzymes necessary for purine and pyrimidine synthesis, thus causing cell-cycle arrest in the S phase. Bortezomib, a proteasome inhibitor, interferes with the cytosolic protein degradation machinery, namely the ubiquitin-proteasome complex, causing breakdown of cell-cycle regulators and cell-cycle arrest. Cetuximab is a chimeric mouse-human antibody that inhibits ligand-dependent activation of the epidermal growth factor receptor, resulting in receptor internalization and inhibition of downstream pathways that, in turn, causes cell growth and progression. All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way.

Key Words. Lung cancer • Pemetrexed • Bortezomib • Cetuximab

This article has been cited by other articles:

				E. N. Vinageras, A. de la Torre, M. O. Rodriguez, M. C. Ferrer, I. Bravo, M. M. del Pino, D. A. Abreu, S. A. Brooks, R. Rives, C. del Castillo Carrillo, et al. Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 20, 2008; 26(9): 1452 - 1458. [Abstract] [Full Text] [PDF]

				I. Velikyan, A. L. Sundberg, O. Lindhe, A. U. Hoglund, O. Eriksson, E. Werner, J. Carlsson, M. Bergstrom, B. Langstrom, and V. Tolmachev Preparation and Evaluation of 68Ga-DOTA-hEGF for Visualization of EGFR Expression in Malignant Tumors J. Nucl. Med., November 1, 2005; 46(11): 1881 - 1888. [Abstract] [Full Text] [PDF]